Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difenpiramide SCHEMBL29238669 | 0.91 | KMT2A (1.00) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| Difenpiramide SCHEMBL23833 | 0.91 | KMT2A (1.00) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL6490488 | 0.87 | KMT2A (0.74) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL29270879 | 0.87 | KMT2A (1.00) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL19555122 | 0.87 | KMT2A (0.77) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL2815739 | 0.86 | KMT2A (0.63) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL28194116 | 0.84 | KMT2A (0.68) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL4575591 | 0.84 | KMT2A (0.68) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL6245092 | 0.83 | GAA (1.00) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL7776518 | 0.83 | GAA (0.83) | KMT2AMEN1SLC6A2SLC6A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536721-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2012-12-26 | — | — | EP | claimed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| CN-119143757-A | Synthesis method of 3-benzyl imidazo [1,5-a ] pyridine-1-carboxylic acid ethyl ester | 南通大学 | 2024-12-17 | — | — | CN | disclosed |
| CN-110252351-B | Application of copper catalyst in catalyzing reaction of 1-pyridyl indole compound and tert-butyl nitrite | 苏州大学 | 2021-12-10 | — | — | CN | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20080269494-A1 | Process for the Preparation of Alpha-Aryl-Alpha-Piperid-2-Yl-Acetamides and the Acid Hydrolysis Thereof | ARCHIMICA S.R.L. (IT) | 2008-10-30 | — | — | US | disclosed |
| EP-1868996-A1 | A PROCESS FOR THE PREPARATION OF ALPHA-ARYL-ALPHA-PIPERID-2-YL-ACETAMIDES AND THE ACID HYDROLYSIS THEREOF | Archimica S.r.l. (IT) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006064052-A1 | A PROCESS FOR THE PREPARATION OF ALPHA-ARYL-ALPHA-PIPERID-2-YL-ACETAMIDES AND THE ACID HYDROLYSIS THEREOF | ARCHIMICA S.R.L. (IT) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269494-A1 | Process for the Preparation of Alpha-Aryl-Alpha-Piperid-2-Yl-Acetamides and the Acid Hydrolysis Thereof | ADRA2A, ARSA, CYP1A2 | KMT2A 133/4885MEN1 4436/4885SLC6A2 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.